2018
DOI: 10.1186/s12885-018-4758-y
|View full text |Cite
|
Sign up to set email alerts
|

ALDH1A3 upregulation and spontaneous metastasis formation is associated with acquired chemoresistance in colorectal cancer cells

Abstract: BackgroundEfficiency of colorectal carcinoma treatment by chemotherapy is diminished as the resistance develops over time in patients. The same holds true for 5-fluorouracil, the drug used in first line chemotherapy of colorectal carcinoma.MethodsChemoresistant derivative of HT-29 cells was prepared by long-term culturing in increasing concentration of 5-fluorouracil. Cells were characterized by viability assays, flow cytometry, gene expression arrays and kinetic imaging. Immunomagnetic separation was used for… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

4
39
0

Year Published

2018
2018
2022
2022

Publication Types

Select...
9
1

Relationship

2
8

Authors

Journals

citations
Cited by 47 publications
(43 citation statements)
references
References 49 publications
4
39
0
Order By: Relevance
“…Despite the fact, that cisplatin-resistant NOY-1 CisR cells were also significantly more resistant to the ALDH inhibitors and napabucasin (STAT3 inhibitor downregulating ALDH expression), these drugs efficiently decreased ALDH activity of resistant cells. Inhibition of the ALDH activity might be a promising therapeutic approach to target the CSCs and to increase the effectiveness of other cancer therapies [26,27]. Based on the data showing the CSC phenotype in the chemoresistant cells, we decided to examine the potential of the CSC targeting agents to revert the cisplatin resistance in the NOY-1 CisR cells.…”
Section: Discussionmentioning
confidence: 99%
“…Despite the fact, that cisplatin-resistant NOY-1 CisR cells were also significantly more resistant to the ALDH inhibitors and napabucasin (STAT3 inhibitor downregulating ALDH expression), these drugs efficiently decreased ALDH activity of resistant cells. Inhibition of the ALDH activity might be a promising therapeutic approach to target the CSCs and to increase the effectiveness of other cancer therapies [26,27]. Based on the data showing the CSC phenotype in the chemoresistant cells, we decided to examine the potential of the CSC targeting agents to revert the cisplatin resistance in the NOY-1 CisR cells.…”
Section: Discussionmentioning
confidence: 99%
“…(Grillet et al, 2017) subtypes of CRC attain the ability to disrupt drug transport, dysregulate cellular processes, alter drug sensitivity (via genetic or epigenetic modifications) and targets of therapy, that subsequently limit the efficacy of existing anti-cancer therapies (Holohan et al, 2013;Panczyk, 2014;Hu et al, 2016;Zhang and Wang, 2017;Hon et al, 2018;Abu et al, 2019). Since there are hints that metastasis and chemoresistance can be interconnected (Zheng, 2017;Durinikova et al, 2018), the previous can be prevented if chemoresistant subtypes are identified early for optimal or more aggressive treatment. Unfortunately, the mechanisms responsible for chemotherapy resistance by CRC have not been clearly identified.…”
Section: Possible Solution To Crc Chemoresistancementioning
confidence: 99%
“…Metastasis is intricately linked with resistance to chemotherapy, both clinically and biologically, but the molecular basis for this link is unknown [11][12][13]. Numerous studies have demonstrated that acquired chemoresistance is associated with the metastatic and migratory phenotypes of in human colon adenocarcinoma and ovarian cancer cell lines [14,15]. In our previous study, we demonstrated that chemoresistant ovarian cancer cells acquired epithelial-to-mesenchymal transition (EMT) and stemness phenotype.…”
Section: Introductionmentioning
confidence: 98%